Mayo Clinic Validation of the MiCK Assay
This study will be conducted in two phases.
During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech
MiCK assay laboratory to determine the ease of sample acquisition, processing, transport,
and assay interpretation.
Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed
that the sample acquisition, processing, transport, and assay interpretation are
appropriate, we will proceed with the Demonstration Phase.
During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the
results will be correlated with prior patient therapy, performance status, and extent of
disease.
Observational [Patient Registry]
Observational Model: Cohort, Time Perspective: Prospective
Complete response and survival
1 year
No
Mary Karaus
Study Director
Mayo Clinic
United States: Mayo Clinic IRB
MAYO1000
NCT01770665
June 2012
March 2014
Name | Location |
---|---|
Mayo Validation Support Services 3050 Superior Drive NW | Rochester, Minnesota 55901 |